Morningstar27d
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
For symptomatic ILD/pneumonitis (Grade 2 or greater ... diverse breast cancer tumor environment. With fam-trastuzumab deruxtecan-nxki, a HER2-directed ADC, AstraZeneca and Daiichi Sankyo are ...
Targeted Oncology8d
FDA Expands PATHWAY HER2 (4B5) Test to Include HER2-Ultralow Status
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
pharmaphorum3d
AZ, Daiichi challenge Roche with EU okay for earlier use of Enhertu
The green light from the European Commission means that Enhertu (trastuzumab deruxtecan ... risk of interstitial lung disease (ILD) and pneumonitis with AZ and Daiichi Sankyo's drug.
BioSpace28d
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
For symptomatic ILD/pneumonitis (Grade 2 or greater), promptly initiate ... to address the biologically diverse breast cancer tumor environment. With fam-trastuzumab deruxtecan-nxki, a HER2-directed ...
Le Lézard27d
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
2 ILD/pneumonitis is confirmed ... the biologically diverse breast cancer tumor environment. With fam-trastuzumab deruxtecan-nxki, a HER2-directed ADC, AstraZeneca and Daiichi Sankyo are aiming ...
The Huntsville Item28d
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
For symptomatic ILD/pneumonitis (Grade 2 or greater ... collaboration to jointly develop and commercialize fam-trastuzumab deruxtecan-nxki in March 2019 and DATROWAY in July 2020, except in ...
The American Journal of Managed Care16d
FDA Approves Trastuzumab Deruxtecan for HER2-Low/Ultralow Breast Cancer
The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.
Indiatimes12d
How to manage respiratory infections like Pneumonia
Pneumonia is a lung infection caused by bacteria, viruses, fungi, or tuberculosis. Symptoms include fever, cough, chest pain, and shortness of breath. Early diagnosis and treatment are crucial to ...
clinicaladvisor.com16d
Enhertu Approved for HR+, HER2-Low/Ultralow Metastatic Breast Cancer
In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA) has ...